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embers of the protein kinase C (PKC) isozyme
family are important signal transducers in virtually
every mammalian cell type. Within the heart, PKC
isozymes are thought to participate in a signaling network that
programs developmental and pathological cardiomyocyte
hypertrophic growth. To investigate the function of PKC
signaling in regulating cardiomyocyte growth, adenoviral-
mediated gene transfer of wild-type and dominant negative
mutants of PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, and 
 
 
 
 (only wild-type 
 
 
 
) was
performed in cultured neonatal rat cardiomyocytes.
Overexpression of wild-type PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, and 
 
 
 
 revealed
distinct subcellular localizations upon activation suggesting
unique functions of each isozyme in cardiomyocytes. Indeed,
overexpression of wild-type PKC
 
 
 
, but not 
 
 
 
II, 
 
 
 
, 
 
 
 
, or 
 
 
 
induced hypertrophic growth of cardiomyocytes character-
M
 
ized by increased cell surface area, increased [
 
3
 
H]-leucine
incorporation, and increased expression of the hypertrophic
marker gene atrial natriuretic factor. In contrast, expression
 
of dominant negative PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, and 
 
 
 
 revealed a necessary
 
role for PKC
 
 
 
 as a mediator of agonist-induced cardio-
myocyte hypertrophy, whereas dominant negative PKC
 
 
 
reduced cellular viability. A mechanism whereby PKC
 
 
 
might regulate hypertrophy was suggested by the observations
that wild-type PKC
 
 
 
 induced extracellular signal–regulated
kinase1/2 (ERK1/2), that dominant negative PKC
 
 
 
 inhibited
PMA-induced ERK1/2 activation, and that dominant negative
MEK1 (up-stream of ERK1/2) inhibited wild-type PKC
 
 
 
–
induced hypertrophic growth. These results implicate PKC
 
 
 
 as
a necessary mediator of cardiomyocyte hypertrophic growth,
in part, through a ERK1/2-dependent signaling pathway.
 
Introduction
 
The mammalian myocardium undergoes a period of devel-
opmental hypertrophic growth during postnatal maturation
that is characterized by the enlargement of individual car-
diomyocytes, without cell division. Aspects of developmental
hypertrophy are reemployed in the adult heart in response to
diverse pathophysiologic stimuli such as hypertension, ischemic
heart disease, valvular insufficiency, and cardiomyopathy
(for review see Lorell and Carabello, 2000). Although
such hypertrophic growth is initially beneficial in adapt-
ing cardiac function, prolonged states of adult hypertro-
phy are a leading predictor for the development of ar-
rhythmias, sudden death, and heart failure (Levy et al.,
1990; Ho et al., 1993). Both pathophysiologic and devel-
opmental hypertrophy of the myocardium are regulated
by endocrine, paracrine, and autocrine growth factors that
activate membrane-bound receptors resulting in signal
transduction through discrete G-proteins and kinase cas-
cades (for review see Molkentin and Dorn, 2001). In turn,
intermediate signal transduction cascades regulate both
cytoplasmic and transcriptional machinery to augment
gene transcription and protein accumulation as part of the
hypertrophic program.
The protein kinase C family of calcium and/or lipid-activated
serine-threonine kinases function downstream of nearly
all membrane-associated signal transduction pathways
(Molkentin and Dorn, 2001). Approximately 12 different
isozymes comprise the PKC family, which are broadly classi-
fied by their activation characteristics. The conventional
PKC isozymes (PKC
 
 
 
, 
 
 
 
I, 
 
 
 
II, and 
 
 
 
) are calcium- and
lipid-activated, whereas the novel isozymes (
 
 
 
, 
 
 
 
, 
 
 
 
, and 
 
 
 
)
and atypical isozymes (
 
 
 
, 
 
 
 
, v, and 
 
 
 
) are calcium indepen-
dent but activated by distinct lipids (for review see Dempsey
et al., 2000). Once activated, PKC isozymes translocate to
discrete subcellular sites through direct interactions with
docking proteins termed receptors for activated C kinases
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(RACKs)* (Mochly-Rosen, 1995), which permit specific
substrate recognition and subsequent signal transduction.
Different PKC isozymes or broad groups associate with
unique RACKs as an important mechanism for regulating
differential target specificities in vivo (Mochly-Rosen, 1995).
A number of reports have associated PKC activation with
either cardiac hypertrophy, heart failure, ischemic injury, or
agonist stimulation. For example, hemodynamic pressure
overload stimulation in rodents can promote efficient trans-
location of PKC
 
 
 
, 
 
 
 
, 
 
 
 
, 
 
 
 
, and 
 
 
 
 (Gu and Bishop, 1994; Ja-
lili et al., 1999; Takeishi et al., 1999; De Windt et al.,
2000). In cultured cardiomyocytes, diverse agonist and stress
stimuli are also potent stimulators of PKC isozyme translo-
cation (Clerk et al., 1996; Goldberg et al., 1997; Gray et al.,
1997; Sil et al., 1998; Rohde et al., 2000). Using pharmaco-
logic inhibitors, PKC activation has been implicated in regu-
lating molecular events associated with agonist-induced car-
diomyocyte hypertrophy (Glembotski et al., 1993; Yamazaki
et al., 1995; Schluter et al., 1997; Sil et al., 1998). Isozyme-
specific peptide inhibitors have also been employed in cul-
tured cardiomyocytes and in transgenic mice to afford
greater specificity of PKC inhibition. Specifically, overex-
pression of a PKC
 
 
 
 C
 
2
 
 domain peptide in cardiomyocytes
blocked phorbol ester–mediated calcium channel activity
(Zhang et al., 1997), while PKC
 
 
 
 inhibitory peptide or acti-
vating peptide affected inotropy and ischemia-induced cellu-
lar injury (Johnson et al., 1996a; Gray et al., 1997; Dorn et
al., 1999).
More recently, transgenic mice have been generated with
altered PKC isozyme signaling in the heart. Overexpression
of either wild-type or a constitutively active deletion mutant
of PKC
 
 
 
 in a mouse heart was reported to induce cardiomy-
opathy (Bowman et al., 1997; Wakasaki et al., 1997), but
more recent investigation has suggested that lower levels of
expression or adult onset PKC
 
 
 
 activation benefits cardiac
contractility and ischemic recovery (Tian et al., 1999;
Huang et al., 2001). Three groups have also reported trans-
genic mice with altered PKC
 
 
 
 activity in the heart. Expres-
sion of a PKC
 
 
 
-activating peptide in the mouse heart was as-
sociated with a physiologic activation of PKC
 
 
 
 and an
increase in myocyte cell number, but not cellular hypertro-
phy (Mochly-Rosen et al., 2000). In contrast, overexpres-
sion of an activated mutant PKC
 
 
 
 in the mouse heart was
reported to induce significant cardiac hypertrophy (Takeishi
et al., 2000), but such a result is likely dependent on the ab-
solute levels of PKC
 
 
 
 overexpression and activity (Pass et al.,
2001). Although a number of studies have demonstrated as-
sociations between various PKC isozymes and cardiac hyper-
trophy, the necessary and sufficient functions of specific
PKC isozymes in the heart have not been established.
To evaluate potential functional divergence amongst PKC
isozymes in regulating cardiomyocyte hypertrophy, cultured
neonatal cardiomyocytes were subjected to adenoviral-medi-
ated gene transfer of wild-type and dominant negative mu-
tants of PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, 
 
 
 
, and 
 
 
 
 (
 
 
 
 wild-type only). PKC
 
 
 
was the only isozyme tested that was capable of inducing a
hypertrophic response characterized by enhanced sarcomeric
organization, increased cell surface area, increased atrial
natriuretic factor (ANF) expression, and increased [
 
3
 
H]-leu-
cine incorporation. Similarly, dominant negative PKC
 
 
 
, but
not dominant negative 
 
 
 
II, 
 
 
 
, and 
 
 
 
, suppressed agonist-
 
*Abbreviations used in this paper: ANF, atrial natriuretic factor; ERK1/2,
extracellular signal–regulated kinase1/2; JNK, c-Jun NH
 
2
 
-terminal ki-
nase; MAPK, mitogen-activated protein kinase; moi, multiplicity of in-
fection; PE, phenylephrine; pfu, plaque forming units; RACK, receptor
of activated C kinases.
Figure 1. Adenoviral-mediated gene transfer of wild-type PKC , 
 II,  , and   in cardiomyocytes. (A) Western blot analysis for anti-
body cross-reactivity from PKC ,  II,  , and   from AdPKC , 
AdPKC II, AdPKC , AdPKC , or control Ad gal-infected neonatal 
cardiomyocytes. (B) Western blot analysis of cytosolic and particulate 
subcellular protein distribution of each PKC isoform at baseline or 
after stimulation with PMA. Distribution of both endogenous and 
overexpressed protein are shown. (C) Histogram representation of 
PKC particulate (open area) and soluble (dark area) protein levels 
demonstrates a 5–6-fold increase in protein expression (P   0.05). 
Results were averaged from three independent experiments. 
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induced cardiomyocyte hypertrophy. PKC
 
 
 
-dependent reg-
ulation of cardiomyocyte hypertrophy was shown to require
extracellular signal–regulated kinase1/2 (ERK1/2) activa-
tion, suggesting a downstream mechanism of action. Collec-
tively, these results implicate PKC
 
 
 
 as a critical regulator of
cardiomyocyte hypertrophic growth.
 
Results
 
Characterization of PKC isozyme 
subcellular localization
 
Adenoviral-mediated gene transfer into cultured neonatal
cardiomyocytes was employed to evaluate the necessary and
sufficient functions of selected PKC isozymes in regulating
hypertrophic growth. Western blotting was performed from
AdPKC
 
 
 
-, AdPKC
 
 
 
II-, AdPKC
 
 
 
-, or AdPKC
 
 
 
-infected
cardiomyocytes to verify the integrity of each PKC isozyme–
encoding adenovirus, to quantify overexpression levels, and
to evaluate antibody specificity (multiplicity of infection
[moi] of 100 plaque forming units [pfu]/ml, resulting in
 
 
 
95% infectivity). The data showed no cross-reactivity be-
tween any of the four isozyme-specific antibodies used, al-
though nonspecific bands were observed with PKC
 
 
 
 and
PKC
 
 
 
 antibody (Fig. 1 A). Western blot quantitation re-
vealed a 5–7-fold increase in protein expression relative to
endogenous levels (Fig. 1, B and C). To verify that adeno-
viral-mediated overexpression did not compromise PKC
regulation or the ability to translocate in cardiomyocytes,
membrane (particulate), and cytosolic (soluble) protein ex-
tracts were generated and subjected to Western blot analysis.
The data demonstrate that PMA (200 nM) induced a simi-
lar profile of cytosolic and membrane-associated protein re-
distribution between endogenous and overexpressed PKC
isozymes (Fig. 1, B and C). These results indicate that ade-
noviral-mediated PKC overexpression gives the same ratio of
membrane and cytosolic localization as compared with their
endogenous isozyme. However, wild-type PKC isozyme
overexpression also increased the total PKC localization to
the membrane protein fraction at baseline, suggesting in-
creased activity (Fig. 1, B and C).
Characterization of PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, and 
 
 
 
 subcellular local-
ization is currently an area of ongoing investigation, which has
been complicated by inadequate antibodies, epitope masking,
and by low levels of endogenous protein in cardiomyocytes.
To further evaluate the subcellular localization and redistribu-
tion profile of PKC
 
 
 
, 
 
 
 
II, 
 
 
 
, and 
 
 
 
, immunocytochemistry
was performed in cardiomyocytes infected with each PKC-
expressing adenovirus. However, the specificity of each PKC
isozyme antibody was first evaluated by immunocytochemis-
try in AdPKC
 
 
 
-, AdPKC
 
 
 
II-, AdPKC
 
 
 
-, and AdPKC
 
 
 
-
infected cardiomyocytes, which revealed no cross-reactivity
and further validated the integrity of each antibody (Fig. 2 A).
At baseline, PKC
 
 
 
, 
 
 
 
II, and   were each broadly distributed
in a diffuse pattern in unstimulated cardiomyocytes, consistent
with their predominant localization to the cytosolic protein
fraction (Fig. 2 B). PKC  also demonstrated a diffuse pattern
of localization at baseline, although a significant concentra-
tion was observed surrounding the nucleus (Fig. 2 B). After
30 min of PMA or phenylephrine (PE) stimulation, each
PKC isozyme demonstrated a distinct redistribution pattern
(Fig. 2 B). Specifically, PKC  protein became localized in a
perinuclear pattern and with a microtubule-like network (see
below). PKC II protein translocated to a punctate pattern
throughout the cell with focal concentrations at cell–cell con-
Figure 2. Adenoviral-mediated gene transfer of PKC ,  II,  , and   
in neonatal cardiomyocytes demonstrates distinct subcellular 
localization and translocation after agonist treatment. (A) Immuno-
cytochemical analysis of PKC antibody specificity from AdPKC -, 
AdPKC II-, AdPKC -, and AdPKC -infected cardiomyocytes. Anti-
bodies are shown on the top while viral infection is shown on the left. 
(B) PKC isozyme distribution was characterized before and after PMA 
or PE treatment. Similar results were obtained in three independent 
experiments. The arrows show areas of significant redistribution after 
agonist stimulation. (C) PKC  shows efficient translocation to the 
particulate fraction only in previously hypertrophied cardiomyocytes.908 The Journal of Cell Biology | Volume 156, Number 5, 2002
tacts. PKC  demonstrated a significant redistribution of
protein to within the nucleus, whereas PKC  showed an
increased association with the sarcomeres (Fig. 2 B). Collec-
tively, the unique patterns of PKC ,  II,  , and   subcellular
redistribution in neonatal cardiomyocytes suggests different
regulatory roles for each isozyme.
Figure 3. Adenoviral-mediated gene transfer of wild-type 
PKC  is sufficient for cardiomyocyte hypertrophy. (A)  -actinin 
(orange) or ANF (green) coimmunostained cardiomyocyte cultures 
reveal myocyte morphology, sarcomeric organization, and 
hypertrophic ANF expression (arrows show perinuclear ANF 
protein expression). (B) Cardiomyocyte cell surface areas were 
quantified from serum-free, Ad gal-, Ad gal  PE–, AdPKC -, 
AdPKC II-, AdPKC -, AdPKC -, and AdPKC -infected cultures. 
 -Actinin–stained cells were imaged and surface areas were 
calculated with NIH Image software (n   100 cells each). (C) 
Percentage of cardiomyocytes expressing ANF protein. (n   25 
fields at 400  magnification). (D) Quantification of relative 
[
3H] leucine incorporation per  g protein normalized as percent-
age of control. (E) PKC-specific kinase assay shows a significant increase in activity from overexpression of each isoform. Results were 
averaged from three independent experiments for A–D, and a representative experiment is shown for E. *P   0.05 vs. Ad gal, 
#P   0.05 vs. 
Ad gal   PE, 
†P   0.05 vs. Ad gal   PMA.PKC isoforms and cardiomyocyte hypertrophy | Braz et al. 909
We also attempted to examine the subcellular localization
and redistribution pattern of endogenous PKC ,  II,  , and
  in cardiomyocytes. However, only endogenous PKC  and
PKC  were reasonably detectable using standard immunocy-
tochemical techniques and the specific antibodies used here
(Fig. 2 A). Although somewhat faint, PKC  and PKC  anti-
body reactivity was observed in a nuclear and perinuclear pat-
tern, respectively, consistent with their localization pattern
observed by overexpression (Fig. 2 A). Endogenous PKC II
and PKC  were not readily detected in neonatal cardiomyo-
cytes using the antibodies described here (see Discussion).
The observation that PE induced PKC  translocation by
immunocytochemistry is in contrast to four previous reports
that failed to identify significant PKC  translocation to the
particulate fraction after either PE or endothelin-1 stimulation
of cardiomyocytes (Clerk et al., 1994, 1996; Deng et al., 1998;
Hayasaki-Kajiwara et al., 1999). However, our analysis of
translocation was performed in previously hypertrophied car-
diomyocytes (stimulated with 2% fetal bovine serum for 24 h),
which act in a more physiologic manner compared with
smaller atrophic myocytes. Indeed, PE stimulation did not
promote translocation of PKC  in atrophic myocytes, but sig-
nificant translocation was readily observed in previously hyper-
trophied myocytes (Fig. 2 C, last lane) (see Discussion).
PKC  uniquely induces hypertrophic growth
Although a large number of studies have demonstrated ac-
tivation of PKC isozymes in association with cardiac hy-
pertrophic growth, evidence of direct causality has not
been established. To this end, each PKC isozyme was over-
expressed in neonatal cardiomyocytes by adenoviral infec-
tion to evaluate their ability to induce hypertrophic
growth. In serum-free medium, neonatal cardiomyocytes
infected with a control  -galactosidase–expressing adeno-
virus (Ad gal) showed an atrophic phenotype without sig-
nificant ANF protein expression (Fig. 3 A). However,
 -adrenergic agonist (PE) stimulation invoked sarcomeric
organization, an increase in cell size, and ANF protein ex-
pression (perinuclear) (Fig. 3 A). Interestingly, overexpres-
sion of PKC II,  ,  , and   did not stimulate hypertrophic
growth or ANF expression after 48 h (Fig. 3 A). In con-
trast, overexpression of wild-type PKC  promoted signifi-
cant sarcomeric organization, increased cell size, and in-
creased ANF protein expression (Fig. 3 A). Quantitation of
three independent experiments demonstrated significantly
greater cell surface area, percentage of cells expressing
ANF, and [
3H]-leucine incorporation in AdPKC , but not
AdPKC II-, AdPKC -, AdPKC -, or AdPKC -infected
neonatal cardiomyocytes (Fig. 3, B–D) (P   0.05). Al-
Figure 4. Adenoviral-mediated gene transfer of PKC  in rat neonatal cardiomyocytes colocalizes with  -tubulin. (A) Immunocytochemical 
analysis of PKC  translocation at progressive times after PMA stimulation. (B) Costaining for PKC  (green) and  -tubulin (red) demonstrates 
coincident immunoreactivity. (C) As a control, neither AdPKC , Ad gal, nor PMA altered the normal pattern of  -tubulin localization. Similar 
results were observed in three independent experiments.910 The Journal of Cell Biology | Volume 156, Number 5, 2002
though these results suggest that PKC  is a unique inducer
of cardiomyocyte growth, it was also important to verify
the integrity of each adenoviral-expressed isozyme. To this
end, PKC-specific enzymatic assays were performed from
AdPKC -, AdPKC II-, AdPKC -, AdPKC -, and AdPKC -
infected cardiomyocytes, which each demonstrated an
 5-fold increase in kinase activity compared with no in-
fection or Ad gal infection (P   0.05) (Fig. 3 E). In addi-
tion, control and AdPKC-infected cardiomyocytes were
also stimulated with PE or PMA for 30 min to evaluate in-
duction of kinase activity. PMA induced a further  7-fold
increase in kinase activity in AdPKC  and AdPKC II in-
fected cardiomyocytes, while AdPKC  and AdPKC  in-
fected cells showed an  3-fold increase in kinase activity
Figure 5. Adenoviral-mediated gene transfer of multiple PKC 
isozymes does not alter PKC  subcellular localization. (A) 
Immunocytochemical analysis of PKC  translocation in cardiomyo-
cytes coinfected with AdPKC  in conjunction with either AdPKC II, 
AdPKC , or AdPKC . (B) Western blot analysis of PKC  protein 
from similarly infected cardiomyocytes reveals no significant 
disruption of endogenous PKC  subcellular localization by 
overexpression of other PKC isozymes. (C) Histogram representation 
of PKC particulate (open area) and cytosolic (dark area) protein 
levels (n   3 experiments). Adenoviral-mediated expression and 
redistribution of PKC  was not reduced by coexpression of PKC II, 
 , or   (P   0.05).PKC isoforms and cardiomyocyte hypertrophy | Braz et al. 911
(P   0.05) (Fig. 3 E). A similar profile, albeit less robust,
was observed after PE stimulation (Fig. 3 E).
Activated PKC  colocalizes with  -tubulin 
in neonatal cardiomyocytes
Since PKC  appeared to uniquely induce cardiomyocyte hy-
pertrophy in culture, it was of interest to more carefully ex-
amine its subcellular localization. A time course of PMA-
induced redistribution of PKC  was first performed, which
demonstrated detectable movement by 15 min of stimula-
tion that reached a maximum by 60 min (Fig. 4 A). The
observed localization of activated PKC  suggested an as-
sociation with a filamentous or tubular network. Indeed,
activated PKC  localization was coincident with  -tubulin
as assessed by confocal microscopy with individual antibod-
ies (PKC  is green and  -tubulin is red) (Fig. 4 B). As an
important control, neither Ad gal infection, AdPKC  infec-
tion, nor PMA stimulation altered the endogenous pattern of
 -tubulin localization, suggesting that the observed colocal-
ization between activated PKC  and  -tubulin does not re-
sult from alterations in  -tubulin localization (Fig. 4 C).
PKC  localization is not affected 
by PKC II,  , or   overexpression
Overexpression of PKC ,  II,  , and   revealed distinct subcel-
lular localizations in cardiomyocytes, suggesting unique dock-
ing complexes between each of these PKC isozymes. However,
it was of concern that overexpression of one PKC isozyme
might influence the docking and subcellular distribution of
other isozymes. To control for secondary effects associated with
isozyme-specific overexpression, AdPKC  was coinfected with
either AdPKC II, AdPKC , or AdPKC  and the ability of
PKC  to undergo the proper redistribution was analyzed by
immunocytochemistry. Overexpression of PKC II,  , and  
did not affect PKC  localization in unstimulated cardiomyo-
cytes, nor did it affect PMA-induced PKC  redistribution to
the tubulin-associated network (Fig. 5 A) (moi 100 pfu/ml).
To further assess potential nonspecific effects associated
with overexpression, Western blotting was performed using
coinfected cardiomyocytes at baseline or after PMA stimula-
tion. Such an analysis was performed for both endogenous
and overexpressed PKC  in the presence of PKC II,  , and
  overexpression (Fig. 5 B). Specifically, the translocation of
endogenous PKC  in response to PMA was not affected by
overexpression of PKC II,  , and   (Fig. 5 B). Furthermore,
overexpressed PKC  also demonstrated a similar profile
of PMA-induced redistribution, even in the presence of
PKC II,  , and   overexpression (Fig. 5 B). Identical results
were observed and quantified in three independent experi-
ments (Fig. 5 C). Collectively, these results indicate that spe-
cific PKC isozyme overexpression does not significantly alter
the activity or other PKC isozymes. These results further
suggest that the hypertrophic response induced by PKC 
overexpression is likely an intrinsic function of this isozyme
and not the result of indirect effects on other PKC isozymes.
PKC  is uniquely required for 
cardiomyocyte hypertrophy
It was of interest to examine the requirement of PKC
isozyme–specific activities as necessary mediators of agonist-
induced cardiomyocyte hypertrophic growth. Accordingly,
adenoviral vectors expressing dominant negative mutants of
PKC ,  II,  , and   were used in cardiomyocytes. Each
dominant negative mutant encodes the full-length protein,
but contains a single amino substitution in a critical ATP
binding residue, rendering the kinase inactive (Ohba et al.,
1998; Matsumoto et al., 2001). Previous work has demon-
strated that such mutations in PKC generate effective domi-
nant negative proteins (Li et al., 1996; Hong et al., 1999;
Pass et al., 2001; Strait et al., 2001). As assessed by Western
blotting from three independent experiments, adenoviral in-
fection at an moi of 100 pfu/ml resulted in  7–9-fold
higher levels of each dominant negative isozyme 48 h
postinfection compared with the wild-type isozymes (Fig. 6,
A and B).
To examine the necessity of PKC isozyme activation
in regulating hypertrophic growth, cardiomyocytes over-
expressing each dominant negative isozyme were stimu-
lated with the  -adrenergic agonist PE. As a control, a
mitogen-activated protein kinase (MAPK) phosphatase-1
(MKP-1)-expressing adenovirus was included as an estab-
lished inhibitor of agonist-induced hypertrophy through
MAPK blockade (Bueno et al., 2001). The data dem-
onstrate that AdPKC dn and AdPKC dn each attenu-
ated or blocked PE-induced sarcomeric organization,
increased surface area, ANF protein expression, and [
3H]-
Figure 6. Adenoviral-mediated gene transfer of dominant negative 
PKC ,  II,  , and   in neonatal cardiomyocytes. (A) Western blot 
analysis of protein expression levels from AdPKC dn-, AdPKC IIdn-, 
AdPKC dn-, or AdPKC dn-infected cardiomyocytes. (B) Histogram 
representation of total PKC isozyme protein levels demonstrates a 
7–9-fold increase in protein after adenoviral infection compared 
with endogenous wild-type protein levels (n   3).912 The Journal of Cell Biology | Volume 156, Number 5, 2002
leucine incorporation (Fig. 7, A–D). In contrast, Ad-
PKC IIdn and AdPKC dn infection did not attenuate
any parameter of PE-induced cardiomyocyte hypertrophy
(Fig. 7, A–D). Although dominant negative PKC  over-
expression inhibited hypertrophy, a significant loss of in-
fected myocytes was observed, suggesting a primary effect
on cell viability, resulting in a secondary effect on hy-
pertrophy. Indeed, AdPKC dn infection enhanced car-
diomyocyte apoptosis as assessed by terminal deoxynu-
cleotidyltransferase-mediated dUTP nick end labeling
(TUNEL) and poly(ADP-ribose) polymerase (PARP)
protein cleavage, suggesting that PKC  activity is nor-
mally required to maintain cardiomyocyte viability in
culture (unpublished data). However, an important ob-
servation is that PKC  acts as a necessary mediator of
cardiomyocyte hypertrophic growth in culture without
negatively affecting cell viability.
The mechanism of PKC -induced hypertrophy 
utilizes ERK1/2 MAPK
The mechanism whereby overexpression of PKC  promotes
cardiomyocyte hypertrophy is uncertain. However, recent
Figure 7. Assessment of hypertrophy in cardiomyocytes expressing dominant negative PKC isozymes. (A)  -Actinin (orange) and ANF 
(green) coimmunostained cardiomyocyte cultures. (B) Cardiomyocyte cell surface area was quantified from serum-free, Ad gal-, Ad gal   PE–, 
AdMKP-1–, AdMKP-1   PE–, AdPKC dn   PE–, AdPKC IIdn   PE–, AdPKC dn   PE–, and AdPKC dn   PE–infected cultures.  -Actinin–stained 
cells were imaged with confocal microscopy and digitized, and surface areas were calculated with NIH Image software (n   100 cells each). 
(C) Percentage of cardiomyocytes expressing ANF protein (n   25 fields at 400  magnification). (D) Quantification of [
3H] leucine incorporation 
per  g protein. All results were obtained in three independent experiments. *P   0.05 vs. Ad gal. 
†P   0.05 vs. Ad gal   PE.PKC isoforms and cardiomyocyte hypertrophy | Braz et al. 913
investigation in multiple cell types has demonstrated cross-
talk between PKC and MAPK-signaling pathways (Kolch et
al., 1993; Clerk et al., 1994; Schonwasser et al., 1998; Ping
et al., 1999; Rohde et al., 2000; Strait et al., 2001). Accord-
ingly, the activation status of ERK1/2, p38, and c-Jun NH2-
terminal kinase (JNK) were analyzed in neonatal cardiomyo-
cytes overexpressing each wild-type PKC isozyme. Western
blot analyses showed a 3.3-fold increase in ERK1/2 phos-
phorylation in PKC  overexpressing cardiomyocytes and a
mild increase associated with PKC  overexpression (Fig. 8,
A and B). In contrast, PKC II and   overexpression did not
significantly induce ERK1/2 phosphorylation in neonatal
cardiomyocytes (Fig. 8, A and B). Analysis of p38 and JNK
phosphorylation demonstrated no activation associated
with any PKC isozyme overexpression in cardiomyocytes, al-
though control experiments with anisomycin-treated, Ad gal-
infected myocytes showed activation (Fig. 8 A). Collectively,
these results indicate that PKC  and   each uniquely cross-
talk with the ERK1/2 MAPK signaling pathway in cardio-
myocytes. The prominent activation of ERK1/2 associated
with PKC  overexpression also suggests a mechanism of hy-
pertrophic growth regulation (see below).
The interconnectivity between PKC isozymes and MAPK
was further evaluated in PMA-stimulated cardiomyocytes
infected with AdPKC dn, AdPKC IIdn, AdPKC dn, or
AdPKC dn. Interestingly, immunoblotting with phosphor-
ylation-specific antibodies demonstrated a partial inhibition
of ERK1/2 activation in dominant negative PKC -express-
ing cardiomyocytes (Fig. 9 A). In contrast, overexpression of
dominant negative PKC II,  , and   did not significantly
attenuate ERK1/2 activation (Fig. 9 A). Results from three
independent experiments demonstrated a 2.5-fold reduc-
tion in ERK1/2 activation in AdPKC dn-infected cardio-
Figure 8. Overexpression of PKC  and   induces ERK1/2 
phosphorylation. (A) Western blot analysis for ERK1/2, p38, and 
JNK wild-type and phosphorylated forms in AdPKC-infected car-
diomyocytes. Anisomycin was used as a control for JNK and p38 
activation only. (B) Quantitation from three independent experiments 
demonstrates significant ERK1/2 activation induced by AdPKC  and 
  infection compared with Ad gal infection. *P   0.05 vs. Ad gal.
Figure 9. AdPKC dn inhibits PMA-induced ERK1/2 phosphorylation 
in neonatal cardiomyocytes. (A) Western blot analysis of phosphor-
ylated ERK1/2 from AdPKC dn-, AdPKC IIdn-, AdPKC dn-, and 
AdPKC dn-infected cardiomyocytes before and after PMA treatment. 
The amount of total ERK1/2 did not vary. (B) Histogram showing a 
significant decrease in phosphorylated ERK1/2 only with AdPKC dn 
infection (n   3). *P   0.05 vs. Ad gal; 
†P   0.05 vs. Ad gal   PMA.914 The Journal of Cell Biology | Volume 156, Number 5, 2002
myocytes, but no significant inhibition by AdPKC IIdn,
AdPKC dn, or AdPKC dn (Fig. 9 B). p38 and JNK activa-
tion were not affected by any of the four dominant negative
PKC isozymes (unpublished data). Together, these results
further suggest cross-talk between PKC  and ERK1/2 as
part of the mechanism responsible for cardiomyocyte hyper-
trophic growth.
To examine the functional consequence of PKC  and
ERK1/2 cross-talk in regulating cardiomyocyte hyper-
trophic growth, AdPKC  was coinfected with an adeno-
virus expressing a dominant negative mutant of MEK1
(AdMEK1dn). An identical dominant negative MEK1-
encoding adenovirus was shown previously to inhibit
ERK1/2 activity and to block agonist-induced neonatal
cardiomyocyte hypertrophy in culture (Ueyama et al.,
2000). Remarkably, AdMEK1dn attenuated AdPKC -
mediated cardiomyocyte hypertrophy as assessed by gross
morphology, cell surface area, ANF protein expression,
and [
3H]-leucine expression (Fig. 10, A–D). In contrast,
a dominant negative MKK3-expressing adenovirus, which
blocks p38 activation (Li et al., 2001), did not reduce Ad-
PKC -induced cardiomyocyte hypertrophy (Fig. 10, A–D).
These results indicated that PKC  regulates cardio-
myocyte hypertrophic growth, in part through ERK1/2
MAPK activation.
Discussion
PKC isozymes demonstrate unique 
subcellular localizations
Previous analyses of PKC ,  II,  , and   subcellular localiza-
tion in neonatal cardiomyocytes have shown both similar and
Figure 10. Adenoviral-mediated gene transfer of dominant 
negative MEK1 attenuates PKC -induced neonatal cardiomyocyte 
hypertrophy. (A)  -Actinin (orange) and ANF (green) coimmunostained 
cardiomyocyte cultures reveal myocyte-specific morphology and 
sarcomeric organization (nuclei are light blue). AdMEK1dn 
infection, but not AdMKK3dn, attenuates morphologic hypertrophy. 
(B) Cardiomyocyte cell surface areas were imaged and quantified 
using NIH Image software (n   100 cells each). (C) Quantitation of 
the percentage of ANF-positive cardiomyocytes (n   25 fields at 
400  magnification). (D) Quantification of relative [
3H] leucine 
incorporation per  g protein normalized as percentage of control. 
All results were quantified from three independent experiments. 
*P   0.05 vs. Ad gal; 
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dissimilar patterns of localization to the data shown in this re-
port. Mochly-Rosen and colleagues demonstrated endoge-
nous PKC  localization to the perinuclear region of neonatal
cardiomyocytes, although an association with microtubules
was not reported (Disatnik et al., 1994; Johnson et al.,
1996a). Such a pattern of redistribution is interesting given
the known role of microtubules in trafficking intracellular or-
ganelles, vesicles, and large protein complexes between the
nucleus and cell membrane. An association with assembled
 -tubulin might suggest a role for PKC  in either regulating
intracellular trafficking during the hypertrophic response, or
that PKC  interacts with other regulatory factors that also as-
sociate with microtubules. That activated PKC  prominently
redistributes to the perinuclear region (continuous with the
endoplasmic reticular membrane) also suggests a potential
regulatory role given the number of important signaling fac-
tors that have been localized to the perinuclear region (Cdc42,
Pyk2, and cytosolic phospholipase A2) (Hirabayashi et al.,
1999; Klingbeil et al., 2001; Murphy et al., 2001). More sig-
nificantly, the perinuclear region is an important site of reac-
tive calcium regulation through the inositol triphosphate re-
ceptor (Guihard et al., 1997). Collectively, these observations
suggest that PKC  redistribution is associated with sites of re-
active signaling and altered calcium handling.
Mochly-Rosen and colleagues also showed PKC  localiza-
tion to the nucleus and perinucleus, whereas PKC  was lo-
calized in a cross-striated pattern in neonatal cardiomyocytes
(Johnson et al., 1996a; Dorn et al., 1999). Although we
identified a similar pattern of PKC  localization and redis-
tribution, the pattern of PKC  translocation was somewhat
different. Here it was shown that PKC  normally resides in
the perinuclear membrane in unstimulated neonatal cardiac
myocytes, but stimulation with PMA promoted movement
out of the perinuclear region and into the nucleus itself (Fig.
2). PKC II was shown previously to redistribute to the peri-
nuclear area and to filamentous structures at the periphery of
the neonatal cardiomyocyte (Disatnik et al., 1994). We also
observed redistribution to the perinuclear region and the pe-
riphery of the cell, but a significant concentrations of
PKC II was also observed at cell-to-cell contacts upon stim-
ulation with PMA in neonatal cardiomyocytes (Fig. 2). Al-
though all four isozyme-specific antibodies readily detected
their respective isozyme when overexpressed without loss of
specificity, endogenous PKC II and   were not readily de-
tected despite positive accounts in the literature, suggesting
either low protein abundance, partial epitope masking, or
that previous descriptions may have employed antibodies
with different specificity.
That PKC ,  II,  , and   each demonstrate unique sub-
cellular localizations and redistribution patterns upon activa-
tion suggests regulation by isozyme-specific docking com-
plexes. Indeed, PKC ,  II,  , and   have each been shown
to contain unique interacting domains in their NH2 termi-
nus that provide specificity for anchoring proteins (RACKs),
which regulate the specificity of substrate phosphorylation
(for review see Mackay and Mochly-Rosen, 2001). A similar
paradigm of isozyme-specific actions was also observed in
cultured rat pituitary cells in which overexpression of PKC ,
 II,  , and   revealed a unique function for PKC  in regu-
lating prolactin secretion (Akita et al., 1994). Collectively,
numerous studies suggest that overexpression approaches can
be employed to dissect isozyme-specific functions of PKC
factors given the high degree of fidelity by which docking
and substrate recognition are controlled in vivo.
PKC  uniquely induces neonatal cardiomyocyte 
hypertrophic growth
Data implicating PKC isozymes as a regulators of cardio-
myocyte hypertrophy have largely been derived by associa-
tion. Specifically, agonist-induced cardiomyocyte hypertrophy
has been shown to activate a diverse array of intracellular sig-
naling factors, including PKC (for review see Molkentin and
Dorn, 2001). To date, direct evidence implicating a specific
PKC isozyme as a dominant regulator of myocyte hyper-
trophic growth is lacking. In culture, permeabilized neonatal
cardiomyocytes treated with a generalized PKC pseudo-sub-
strate peptide demonstrated reduced [
14C]phenylalanine in-
corporation, suggesting a necessary role of PKC signaling in
general (Johnson et al., 1996b). More recently, adenoviral-
mediated overexpression of a constitutively active mutant of
PKC  was reported to enhance hypertrophic marker gene
expression and to increase cell length, but interestingly,
overexpression did not increase cell surface area or protein-
to-DNA ratio (Strait et al., 2001). In this report, PKC , but
not PKC II,   ,   , or  , induced cardiomyocyte hyper-
trophic growth characterized by increased cell surface area,
[
3H]leucine incorporation and ANF expression.
It was of concern whether simple overexpression of a wild-
type PKC isozyme would function similar to an activation
event of that particular endogenous isozyme. Overexpression
studies of other wild-type signaling factors have demon-
strated efficacy through a net increase in both the activated
and inactivated forms of the given factor, such that the inac-
tivated state is innocuous while the activated state is func-
tional. For example, overexpression of wild-type G q or
G s in the mouse heart was sufficient to activate down-
stream targets (Iwase et al., 1996; D’Angelo et al., 1997).
Consistent with these reports, overexpression of each wild-
type PKC isozyme by adenoviral gene transfer produced
a 5–7-fold increase in particulate association, suggesting
greater activation by mass action.
Additional data examining PKC isozyme functions in reg-
ulating myocyte growth came from the use of transgenic
mice expressing PKC  or PKC  in the heart. Overexpres-
sion of wild-type or an activated deletion mutant of PKC 
in the mouse heart was initially reported to induce a hyper-
trophic response (Bowman et al., 1997; Wakasaki et al.,
1997). However, more recent investigation of PKC  trans-
genic mice suggests that physiologic activation of this
isozyme in the adult heart does not promote cardiomyopathy
and actually benefits cardiac contractility and ischemic re-
covery (Tian et al., 1999; Huang et al., 2001). Indeed, tar-
geted disruption of the PKC  gene in the mouse did not af-
fect the ability of these hearts to undergo hypertrophic
growth (Roman et al., 2001). Similar disparity of interpreta-
tion surrounds the effect of PKC  in the hearts of transgenic
mice. Expression of a PKC  activating peptide in the mouse
heart, which promoted a physiologic activation of PKC , did
not result in cellular hypertrophy (Mochly-Rosen et al.,
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sion of an activated PKC  mutant protein in the mouse
heart promoted cardiac hypertrophy (Takeishi et al., 2000).
However, a third group demonstrated that high levels of
PKC  overexpression promoted hypertrophy and cardiomy-
opathy, while more physiologic levels of expression were
beneficial to the heart and rendered it resistant to myocardial
ischemia (Pass et al., 2001). In general, these previous studies
suggest a level of uncertainty as to whether PKC  or PKC 
regulates the hypertrophic growth of cardiac myocytes.
PKC  is required for neonatal myocyte growth
Overexpression of dominant negative mutants of PKC ,  II,
 , and   in growth-stimulated neonatal cardiomyocytes sug-
gested a necessary role for PKC  and PKC . Such data impli-
cate critical roles for these two latter isozymes as regulators of
myocyte hypertrophy. However, AdPKC dn infection pro-
moted significant terminal deoxynucleotidyltransferase-medi-
ated dUTP nick end labeling (TUNEL) and poly(ADP-ribose)
polymerase (PARP) protein cleavage, suggesting induction of
apoptosis (unpublished data). Consistent with this interpreta-
tion, high levels of PKC  inhibitory peptide expression in the
mouse heart by transgenesis induced a lethal cardiomyopathy,
suggesting a critical role for basal signaling through PKC  in
maintaining cellular homeostasis (Mochly-Rosen et al., 2000).
Such results suggest that the inhibition of cardiomyocyte hy-
pertrophic growth observed with AdPKC dn is secondary to
the loss of cell viability. In contrast, overexpression of domi-
nant negative PKC  did not affect cardiomyocyte viability,
suggesting that inhibition of hypertrophic growth is a direct
mechanism and not due to the health of the cells. These results
are also consistent with the unique ability of PKC  to induce
myocyte hypertrophic growth.
The dominant negative PKC mutations consist of a lysine
to arginine substitution in the ATP binding domain that
render the kinases inactive but still able to interact with en-
dogenous RACKs. Indeed, an identical PKC  dominant
negative mutation (K to R) was recently employed in car-
diac-specific transgenic mice, which demonstrated competi-
tion with wild-type PKC  for RACK2 binding sites in vivo
(Pass et al., 2001). Overexpression of dominant negative
PKC  was also shown to only influence the translocation
and activity of endogenous PKC , and not other PKC
isozymes (Strait et al., 2001). In other cell types, similar ATP
binding site mutations produced potent and isozyme-specific
dominant negative regulatory effects (Li et al., 1996; Hong
et al., 1999; Pass et al., 2001; Strait et al., 2001). The above
studies suggest that overexpression of kinase dead, dominant
negative mutants of each PKC isozyme specifically antago-
nizes the activity of its cognate wild-type isozyme in vivo.
PKC  regulates myocyte growth, in part, 
through ERK MAPK
The interconnectivity between PKC isozymes and MAPK
signaling branches has been previously reported in many
cell-types. In cardiac myocytes, dominant negative PKC 
was shown to down-regulate endothelin-1–induced ERK1/2
activation (Strait et al., 2001), and in another study, agonist-
induced ERK1/2 MAPK activation was correlated with
PKC  activation (Jiang et al., 1996). In adult rabbit car-
diomyocytes, adenoviral-mediated overexpression of PKC 
was reported to activate ERK1/2 MAPK, yet a dominant
negative PKC  mutant was reported to have no effect on
basal ERK1/2 activation (Ping et al., 1999). More recently,
PKC  and PKC  were also shown to be associated with
ERK1/2 activation in cardiac myocytes, suggesting the in-
volvement of other isozymes (Rohde et al., 2000).
In this report, we showed that overexpression of both
PKC  and PKC  induced significant ERK1/2 activation,
but not p38 or JNK. These results are largely consistent
with the reports discussed above. However, we also observed
that dominant negative PKC  antagonized PMA-induced
ERK1/2 activation, whereas dominant negative PKC  did
not. At the functional level, dominant negative MEK1
(blocks ERK1/2 activation) inhibited wild-type PKC -
induced cardiomyocyte hypertrophy, suggesting a critical
role for PKC  and ERK1/2 communication in regulating
cardiomyocyte hypertrophic growth. Previous reports also
support an interconnection between PKC  and ERK1/2
MAPK signaling, although the level at which PKC  inter-
acts with the MAPK cascade is disputed (Kolch et al., 1993;
Schonwasser et al., 1998).
Expression of dominant negative PKC II,  , and   did
not significantly attenuate PMA-induced ERK1/2 activation
in cardiomyocytes. PMA was employed since it acts as a
more specific agonist of cPKC and nPKC activation, whereas
hypertrophic agonists such as PE, endothelin-1, and angio-
tensin II stimulate diverse signaling pathways that could in-
directly promote activation of selected PKC isozymes. In-
deed, the studies discussed above, which demonstrated a role
for PKC  and PKC  in regulating ERK1/2 activity, did not
employ a direct PKC agonist such as PMA. In this manner,
agonists that function through G-protein–coupled receptors
or receptor tyrosine kinases likely utilize additional PKC
isozymes, suggesting a complex relationship between PKC
and ERK1/2 signaling pathways in cardiomyocytes.
The observation that dominant negative PKC  attenu-
ated PE-induced cardiomyocyte hypertrophy, coupled with
the observation that PE augmented PKC  kinase activity
and translocation to discrete intracellular locations by im-
munocytochemistry, suggests that G q-coupled receptor
signaling activates PKC . This assertion is in contrast to
four previous reports that failed to identify significant PKC 
translocation to the particulate fraction after either PE or en-
dothelin-1 stimulation of cardiomyocytes (Clerk et al.,
1994, 1996; Deng et al., 1998; Hayasaki-Kajiwara et al.,
1999). Two explanations may account for these differing re-
sults. First, it is largely assumed that PKC activation is syn-
onymous with the ability to isolate PKC isozymes from a
membrane-enriched or particulate protein fraction. This as-
sumption may not be valid in every cell type or may vary de-
pending on the stimulus and the specific isozyme analyzed.
Second, our analysis of PE-induced PKC  translocation by
immunocytochemistry and kinase activity was performed
with hypertrophied neonatal cardiomyocytes (previously se-
rum-stimulated), which are significantly larger and contain
more organized sarcomeric structures. Cardiomyocytes in
this condition may contain more organized docking units,
which might be more amenable to detection of transloca-
tion. Alternatively, hypertrophied cardiomyocytes might
have more complex membrane–associated signaling com-PKC isoforms and cardiomyocyte hypertrophy | Braz et al. 917
plexes, which could respond differently to PE stimulation.
Indeed, atrophic cardiomyocytes were largely refractory to
PE-induced PKC  translocation (Fig. 2 C). In any event,
the conditions used here demonstrated PE-induced PKC 
translocation and increased kinase activity in cultured cardio-
myocytes that were in a more physiologic state (hypertro-
phied). Future analysis of PKC  signaling effects in animal
models should shed additional light on the physiologic role
of PKC  as a regulator of cardiac hypertrophy.
Materials and methods
Primary cardiomyocyte cell culture
Primary cultures of neonatal rat cardiomyocytes were obtained by enzy-
matic dissociation of 1–2-d-old Sprague-Dawley rat neonates as described
previously (De Windt et al., 2000). Cardiomyocytes were cultured under
serum-free conditions in M199 media (GIBCO BRL) supplemented with
penicillin/streptomycin (100 U/ml) and L-glutamine (2 mmol/L). For analy-
sis of PKC isozyme translocation, cultures were first stimulated with 2%
FBS for 24 h to induce sarcomeric organization.
Replication-deficient adenovirus generation
The generation and characterization of adenovirus-encoding wild-type or
dominant negative mutants of PKC ,  II,  ,  , and   were described previ-
ously (Ohba et al., 1998; Matsumoto et al., 2001) (gift from Dr. Motoi
Ohba, Tokyo, Japan). The dominant negative PKC ,  II,  , and   cDNAs
consisted of a lysine to arginine mutation in the ATP binding domain at
amino acid positions 368, 371, 376, and 436, respectively. Each recombi-
nant adenovirus was plaque purified, expanded, and titered in HEK293
cells using the agarose gel overlay method (Mittereder et al., 1996). Typi-
cal experiments involved infection of neonatal rat cardiomyocytes at a moi
of 100 pfu for 2 h at 37 C in a humidified, 6% CO2 incubator. Subse-
quently, the cells were cultured in serum-free M199 media for an addi-
tional 24 h before treatments or analysis. Under these conditions  95% of
the cells showed expression of the recombinant protein. Selected cultures
were infected at a lower moi of 25 pfu/ml for immunocytochemical analy-
sis so that nonexpressing cells could also be observed and compared with
adenoviral infected cells.
Immunocytochemistry
Cardiomyocytes were prepared for immunocytochemistry as described
previously (Taigen et al., 2000). To assess sarcomeric organization and
cardiomyocyte hypertrophy antibody against  -actinin (EA-53; Sigma-
Aldrich) and ANF (Peninsula Laboratories) were used at a dilution of
1:500. Secondary antibodies included anti–mouse TRITC-conjugated anti-
body (Sigma-Aldrich) and anti–rabbit FITC-conjugated antibody (Sigma-
Aldrich) at a dilution of 1:400. Quantitation of cardiomyocyte cell surface
area was performed on  -actinin–stained cardiomyocytes using confocal
laser microscopy and NIH Image software on a Sun system workstation.
Characterization of PKC ,  II,  , and   isozyme distribution also used con-
focal microscopy in conjunction with polyclonal antiserum purchased
from Santa Cruz Biotechnology, Inc. (each used at 1:400).  -Tubulin anti-
serum (1:400) was purchased from Sigma-Aldrich.
Western blot analysis
Protein extracts were generated from cultured cardiomyocytes as de-
scribed previously (Taigen et al., 2000). Protein samples were subjected to
SDS-PAGE (8% gels), transferred to Hybond-P membrane (Amersham
Pharmacia Biotech), blocked in 7% milk, and incubated with primary anti-
bodies overnight in 3% milk at 4 C. Secondary antibodies IgG (alkaline
phosphatase–conjugated anti–mouse, –rabbit, or –goat) were incubated for
1 h at room temperature in 3% milk (Santa Cruz Biotechnology, Inc.).
Chemifluorescent detection was directly performed with the Vistra ECF re-
agent (RPN 5785; Amersham Pharmacia Biotech) and scanned using a
Storm 860 (Molecular Dynamics). Other antibodies included phospho-
p38, p38, phospho-JNK, JNK wild-type, phospho-ERK1/2, and ERK1/2
(Cell Signaling).
PKC translocation assay tissue preparation and enzymatic assay
Neonatal cardiomyocyte cultures were prepared in homogenization buffer
(25 mM Tris-Cl, pH 7.5, 4 mM EGTA, 2 mM EDTA, 5 mM DTT, 1 mM
PMSF, and 1 ug/ml leupeptin) on ice and subsequently spun at 100,000 g
for 30 min at 4 C. The supernatant product was saved as the cytosolic frac-
tion while the remaining pellet was resuspended in homogenization buffer
with the addition of 1% Triton X-100. The sample was then rehomoge-
nized and incubated on ice for 30 min and spun again at 100,000 g for 30
min at 4 C, and the remaining supernatant fraction was saved as the partic-
ulate sample.
Total PKC activity was determined using a radioactive enzymatic assay
(SignaTECT PKC assay system; Promega) in which cardiomyocyte superna-
tants are passed over a DEAE cellulose column to purify PKC proteins. PKC
activity assays were performed in the presence of phospholipids (phos-
phatidylserine) and a PKC-biotinylated peptide substrate. All reactions
were incubated at 30 C for 5 min, and [
32P] incorporation was measured
by transferring the completed reactions onto membranes (Promega).
Protein synthesis measurements
Rates of protein synthesis in cultured cardiomyocytes were determined by
[
3H]leucine incorporation. Cardiomyocytes were infected with adenovirus
overnight, preincubated with leucine-free RPMI medium for 1 h, and then
incubated with 2.5  Ci/ml [
3H]leucine for 6 h. PE (20  M) or vehicle was
added to the cultures together with leucine-free medium and [
3H]leucine
incorporation was then quantified as described previously (Sadoshima et
al., 1992).
Statistical analysis
Differences between data groups were evaluated for significance using a
Student’s t test of unpaired data or one-way analysis of variance and Bon-
ferroni’s post-test (  standard error of the mean).
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